Sector News

Stryker Announces Definitive Agreement to Acquire Muka Metal, A.S.

July 22, 2015
Life sciences
Stryker Corporation SYK, +0.69% announced today a definitive agreement to acquire Muka Metal, A.S. (“Muka”) in an all cash transaction. Muka, headquartered in Kayseri, Turkey, sells hospital beds, stretchers and related patient room furniture and accessories that serve markets across Turkey and other regions globally.
 
“The acquisition of Muka aligns with our strategy to expand our global presence through existing channels with an established and trusted brand,” said Timothy J. Scannell, Stryker Group President, MedSurg and Neurotechnology. “This acquisition will bolster Stryker Medical’s bed and stretcher offerings, and is a compelling opportunity to drive growth in Turkey and other regions around the world.”
 
Stryker and Muka have maintained a relationship under a distribution agreement for Latin America since 2012, and with this acquisition Stryker will expand its global presence in key markets with a product portfolio that complements and enhances Stryker’s current offerings.
 
Since launching its first hospital bed in 2002, Muka has established itself as a leading manufacturer and marketer of hospital beds, stretchers and related patient room furniture and accessories. Muka finished construction in mid-2014 of a modern, state of the art facility located in a free trade zone within Kayseri.
 
The closing of the transaction is subject to customary closing conditions. Upon closing, the transaction is expected to be neutral to Stryker’s 2015 earnings per share excluding acquisition, integration-related and intangible amortization charges and accretive thereafter. The transaction is expected to close in the third quarter of 2015.
 
Source: Stryker

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach